Update on the COVID-19 pandemic

Information regarding COVID-19 is in constant change, as is the situation regarding vaccination and prioritization for immune-compromised individuals.

If you have any COVID-19-related questions, we’ve created a specific COVID section on our website that can be accessed by clicking here or by selecting the “News & Events” tab from our homepage. In this section, you’ll find the latest news and information about the pandemic in Canada from trustworthy and reliable sources.

Any specific questions that you may have regarding the COVID-19 vaccination, delays between vaccine dosing, and prioritization within your province are best answered by your healthcare team. They’re the ones who know you and your particular situation and are therefore in a position to best address your unique concerns.

Created by, and entirely focused on, Canadians impacted by myeloma, Myeloma Canada is the only national charitable organization committed to providing you with the most up-to-date and reliable information on myeloma. Some of the ways we do this is through our monthly e-newsletter, “Myeloma Matters”, as well as through our social media platforms.

Please don’t hesitate to contact us at contact@myeloma.ca or toll-free at 1-888-798-5771 with any questions regarding our programs and services.

Close

Make a donation

How Will Patients Benefit?

There are numerous benefits for Canadian patients that accrue from the MCRN program. These are some of the major advantages highlighted:

  • Increasing access to more trials, in more centres across Canada
  • Allowing patients access to new molecules or treatment combinations not yet approved by Health Canada
  • Allowing patients access to new molecules or treatment combinations that are not yet reimbursed by the government or private insurance
  • Ensuring the patient voice is heard through patient representation on the Clinical Trial Steering Committee and the Protocol Review Committee
  • Providing real-word evidence through the MCRN Canadian Multiple Myeloma Database to help guide clinical decision-making, ultimately improving patient outcomes
  • Promoting coast-to-coast collaboration, allowing researchers quick access to shared findings and data allowing for improved diagnosis and optimal treatment management
  • Hosting clinical research in Canada may accelerate new treatment approvals by government bodies, by providing real-world Canadian evidence and data